236 related articles for article (PubMed ID: 16189121)
1. Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection.
Zaragoza O; Mihu C; Casadevall A; Nosanchuk JD
Antimicrob Agents Chemother; 2005 Oct; 49(10):4358-61. PubMed ID: 16189121
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans.
Hossain MA; Maesaki S; Kakeya H; Noda T; Yanagihara K; Sasaki E; Hirakata Y; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 1998 Jul; 42(7):1722-5. PubMed ID: 9661011
[TBL] [Abstract][Full Text] [Related]
4. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation.
Sangalli-Leite F; Scorzoni L; Alves de Paula E Silva AC; da Silva JF; de Oliveira HC; de Lacorte Singulani J; Gullo FP; Moraes da Silva R; Regasini LO; Siqueira da Silva DH; da Silva Bolzani V; Fusco-Almeida AM; Soares Mendes-Giannini MJ
Int J Antimicrob Agents; 2016 Nov; 48(5):504-511. PubMed ID: 27742203
[TBL] [Abstract][Full Text] [Related]
6. In vitro interaction of antifungal and antibacterial drugs against Cryptococcus neoformans var. grubii before and after capsular induction.
Rossato L; Loreto ÉS; Venturini TP; Azevedo MI; Weiblen C; Botton SA; Santurio JM; Alves SH
Med Mycol; 2015 Nov; 53(8):885-9. PubMed ID: 26333356
[TBL] [Abstract][Full Text] [Related]
7. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and
Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro antifungal activity of the polyene derivative SPA-S-753 against encapsulated form of Cryptococcus neoformans.
Strippoli V; D'Auria FD; Simonetti N; Basti D; Bruzzese T
Infection; 1997; 25(1):27-31. PubMed ID: 9039534
[TBL] [Abstract][Full Text] [Related]
9. New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans
Lu RY; Ni TJ; Wu J; Yan L; Lv QZ; Li LP; Zhang DZ; Jiang YY
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791946
[TBL] [Abstract][Full Text] [Related]
10. Quercetin and rutin as potential agents antifungal against Cryptococcus spp.
Oliveira VM; Carraro E; Auler ME; Khalil NM
Braz J Biol; 2016; 76(4):1029-1034. PubMed ID: 27166572
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo studies on synergistic antifungal activity.
Shadomy S
Contrib Microbiol Immunol; 1977; 4():147-57. PubMed ID: 342191
[No Abstract] [Full Text] [Related]
12. Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.
Pereira TC; do Carmo PHF; de Menezes RT; de Oliveira HC; de Oliveira LD; Junqueira JC; Scorzoni L
Folia Microbiol (Praha); 2023 Dec; 68(6):999-1004. PubMed ID: 37950840
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
Arechavala AI; Ochiuzzi ME; Borgnia MD; Santiso GM
Rev Iberoam Micol; 2009 Sep; 26(3):194-7. PubMed ID: 19635445
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
15. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Khyriem AB; Sujatha S; Parija SC
Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis.
Joseph-Horne T; Loeffler RS; Hollomon DW; Kelly SL
J Med Vet Mycol; 1996; 34(3):223-5. PubMed ID: 8803806
[TBL] [Abstract][Full Text] [Related]
17. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis.
Block ER; Bennett JE
Proc Soc Exp Biol Med; 1973 Feb; 142(2):476-80. PubMed ID: 4570039
[No Abstract] [Full Text] [Related]
18. Treatment of experimental systemic mycoses with BRL 49594A.
Najvar LK; Luther MF; Graybill JR
J Antimicrob Chemother; 1995 Dec; 36(6):1005-1011. PubMed ID: 8821599
[TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
20. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
